Legend Biotech to Present LB2102 Phase 1 Data and CARTITUDE-4 Analysis at ASCO
Legend Biotech will present preliminary Phase 1 results for LB2102, its DLL3-targeted CAR-T therapy for relapsed or refractory small-cell lung cancer and large-cell neuroendocrine carcinoma, in a rapid oral session at ASCO May 31. It will also reveal CARTITUDE-4 cytogenetic subgroup analysis and IEC-EC incidence data for CARVYKTI®.
1. ASCO Presentation Schedule
Legend Biotech will deliver a rapid oral presentation of preliminary Phase 1 LB2102 data on May 31 at 5:00 p.m. CT (Abstract #8012) and present two posters on June 1 covering CARTITUDE-4 cytogenetic subgroup analysis (Abstract #7536) and IEC-EC incidence in CARVYKTI® trials (Abstract #7533). An on-site investor relations event and webcast will follow on May 31 at 6:15 p.m. CT.
2. Preliminary LB2102 Phase 1 Data
LB2102 is a dnTGFBR2-armored, DLL3-targeted autologous CAR-T therapy being evaluated in relapsed or refractory small-cell lung cancer and large-cell neuroendocrine carcinoma. Early results indicate a manageable safety profile and signs of antitumor activity, supporting Legend Biotech’s strategy to extend CAR-T into solid tumors.
3. CARTITUDE-4 and CARVYKTI® Data
The CARTITUDE-4 subgroup analysis will highlight response rates in high- and standard-risk cytogenetic cohorts following bridging therapy, while the IEC-EC poster examines enterocolitis events across cilta-cel studies. CARVYKTI® is now commercially available in 18 countries and has treated over 10,000 multiple myeloma patients to date.